Biblio
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. PLoS One. 2015;10(7):e0132620.
Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen. Int J Cancer. 2019.
. Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol. 2023.
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: A single-center experience. Ann Transplant. 2014;19:6-12.
Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. Br J Haematol. 2022.
[Research Progress in Treatment of Chronic Lymphocytic Leukemia --Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(6):1910-1915.
. Susceptibility Of Ph-Positive All To Tki Therapy Associated With Bcr-Abl Rearrangement Patterns: A Retrospective Analysis. PLoS One. 2014;9(11):e110431.
Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial. Front Immunol. 2023;14:1269163.
.